CoChat

Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors

Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., Krarup, T. · 2015 · Diabetes, Obesity and Metabolism
Cited by 48

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: To examine whether 12 weeks of treatment with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, sitagliptin, influences the insulin secretion induced by glucose, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) during a hyperglycaemic clamp in patients with type 2 diabetes (T2DM). Methods: A randomized, double‐blind, placebo‐controlled study was conducted over 12 weeks, during which 25 patients with T2DM completed treatment with either sitagliptin (100 mg once daily) or placebo as add‐on therapy to metformin [sitagliptin group (n = 12): mean ± standard error of the mean (s.e.m.) age 54 ± 2.5 years, mean ± s.e.m. HbA1c 7.8 ± 0.2%; placebo group (n = 13): mean ± s.e.m. age: 57 ± 3.0 years, mean ± s.e.m. HbA1c 7.9 ± 0.2 %]. In weeks 1 and 12, the patients underwent three 2‐h 15‐mM hyperglycaemic clamp experiments with infusion of either saline, GLP‐1 or GIP. β‐cell function was evaluated according to first‐phase, second‐phase, incremental and total insulin and C‐peptide responses. Results: In the sitagliptin group, the mean HbA1c concentration was significantly reduced by 0.9% (p = 0.01). The total β‐cell response during GIP infusion improved signficantly from week 1 to week 12, both within the sitagliptin group (p = 0.004) and when compared with the placebo group (p = 0.04). The total β‐cell response during GLP‐1 infusion was significantly higher (p = 0.001) when compared with saline and GIP infusion, but with no improvement from week 1 to week 12. No significant changes in β‐cell function occurred in the placebo group. Conclusions: Treatment with the DPP‐4 inhibitor sitagliptin over 12 weeks in patients with T2DM partially restored the lost insulinotropic effect of GIP, whereas the preserved insulinotropic effect of GLP‐1 was not further improved. A gradual enhancement of the insulinotropic effect of GIP, therefore, possibly contributes to the antidiabetic actions of DPP‐4 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12395

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 48

Metadata

Authors
Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-10-26
Volume
17
Issue
1
Pages
74-81
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2082289458
Cited by
48
References
14
FWCI
2.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors. https://app.cochat.ai/papers/10.1111/dom.12395
The paper
Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2015). Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.